CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Issue Information44
Issue Information42
Issue Information39
Issue Information37
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval34
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients33
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐132
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children31
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery30
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease29
Pharmacometric and statistical considerations for dose optimization28
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models27
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension27
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy26
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report26
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story26
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population25
Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations23
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach22
Issue Information22
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential22
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation21
0.1285879611969